Trial reportBritish journal of clinical pharmacology2026
Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.
Trial report in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.British journal of clinical pharmacology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
aimsKallikrein-kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID-19-associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID-19, we conducted a phase 2, open-label, randomized-controlled, proof-of-concept, interventional trial.
methodsWe recruited 40 patients hospitalized with moderate COVID-19 and randomized them 1:1 to receive either standard-of-care (SoC) treatment or SoC plus intravenous lanadelumab (300 mg on days one and four). The primary outcome consisted of repeated measurements of supplemental oxygen (litres/minute) necessary to maintain a peripheral oxygen saturation (SpO
resultsSufficient endpoint data for the population were available for the first five days, but not for the previsioned 14-day endpoint. Consequently, analysis of the primary endpoint was based on the first five days of treatment. Within this timeframe, lanadelumab did not significantly affect supplemental oxygen volumes. Neither treatment nor interaction between treatment and time was a significant predictor of oxygen volumes in a linear mixed model (p = 0.49 and p = 0.15, respectively). None of the secondary outcomes was significantly affected by lanadelumab. Intravenous lanadelumab was well tolerated.
conclusionsThis exploratory study was evaluated using a shortened primary endpoint period. Lanadelumab showed no indication of benefit on oxygen needs or other clinical outcomes in patients with COVID-19. Lanadelumab was well tolerated throughout the trial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.